- Home
- DHY vs CVRX Comparison
DHY vs CVRX Comparison
Compare DHY & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- CVRX
- Stock Information
- Founded
- DHY 1998
- CVRX 2000
- Country
- DHY United States
- CVRX United States
- Employees
- DHY N/A
- CVRX N/A
- Industry
- DHY Finance/Investors Services
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DHY Finance
- CVRX Health Care
- Exchange
- DHY Nasdaq
- CVRX Nasdaq
- Market Cap
- DHY 217.4M
- CVRX 214.8M
- IPO Year
- DHY N/A
- CVRX 2021
- Fundamental
- Price
- DHY $2.15
- CVRX $8.42
- Analyst Decision
- DHY
- CVRX Buy
- Analyst Count
- DHY 0
- CVRX 6
- Target Price
- DHY N/A
- CVRX $13.60
- AVG Volume (30 Days)
- DHY 569.1K
- CVRX 284.3K
- Earning Date
- DHY 01-01-0001
- CVRX 10-24-2024
- Dividend Yield
- DHY 9.10%
- CVRX N/A
- EPS Growth
- DHY N/A
- CVRX N/A
- EPS
- DHY N/A
- CVRX N/A
- Revenue
- DHY N/A
- CVRX $44,393,000.00
- Revenue This Year
- DHY N/A
- CVRX $30.78
- Revenue Next Year
- DHY N/A
- CVRX $30.41
- P/E Ratio
- DHY N/A
- CVRX N/A
- Revenue Growth
- DHY N/A
- CVRX 43.94
- 52 Week Low
- DHY $1.77
- CVRX $6.40
- 52 Week High
- DHY $2.08
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- DHY 64.06
- CVRX 42.96
- Support Level
- DHY $2.12
- CVRX $8.64
- Resistance Level
- DHY $2.10
- CVRX $10.06
- Average True Range (ATR)
- DHY 0.02
- CVRX 0.67
- MACD
- DHY 0.00
- CVRX -0.02
- Stochastic Oscillator
- DHY 90.00
- CVRX 20.53
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company with the objective to seek high current income and capital appreciation as a secondary objective.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.